Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
about
ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncologyNot All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation DetectionTesting for ROS1 in non-small cell lung cancer: a review with recommendationsReal-world data in the molecular era-finding the reality in the real world.The use of endobronchial ultrasound guided transbronchial needle aspiration specimens for next generation sequencing in non-small cell lung cancer: a clinical perspective.Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAWhat hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).Integrated digital error suppression for improved detection of circulating tumor DNAAnalytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAPrecision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic featuresPersonalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationComprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negativeInstitutional implementation of clinical tumor profiling on an unselected cancer population.Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.Novel investigational therapies for treating biliary tract carcinoma.Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.Resistance to Therapy.Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic.Lung cancer as a paradigm for precision oncology in solid tumours.The importance of test accuracy in economic evaluations of companion diagnostics.Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies.Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patientsAdenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: case report.Liquid biopsy in the practice of neo-oncology
P2860
Q26738387-F565CB79-99F4-41E9-8B94-3C9B9F53B182Q26801745-31F3E19B-C5F7-41D2-8137-EE23754D7183Q28070062-C61FE551-D22C-4211-8C67-B6FD2A39E5A8Q31023009-3664AD99-05F7-474F-931D-AB70E2F836FDQ33639153-32D2279E-7E16-4FE8-B2F3-59220299CBECQ33737740-0558AFCC-72BF-4F10-8FF6-DEC57077F125Q34514469-B06C5A32-757E-4235-800F-A4FC942182C9Q34520008-18664EE6-5D15-4A08-8F0B-16D389F4BDB8Q35810461-67B2AC2E-0AFC-432A-BA62-DAF68AA6A20DQ36288987-FE593B87-0D4B-4403-9079-E390E2A254B7Q36301400-AEE99419-47D4-48D9-9AB2-438E43713832Q36444609-CD76B797-A43C-4441-AE76-FEA173CAF8F6Q36759354-E6CCEC78-26A2-4A70-95B1-66BFC6B7EE47Q36761302-56C407A9-EAC9-4495-93C3-C2A402F44DBCQ37017049-F5524D98-8809-4F8A-AFCB-04A947D1A3CAQ37017060-3446B7A6-BF93-403C-849B-54062E920120Q37041209-6A4E4B80-6D9B-46B1-A048-4C51DA79A18DQ37109885-C6F2D8A7-8EAA-4817-85B9-03CF6EE470F4Q37269251-80309E8C-FF12-44C2-918B-98B1B26AB8D5Q37417570-0A9709EA-140A-40E8-B3B7-FE45A79BD182Q38652369-EAC9112F-CEB9-4940-8DAC-21BA847F254DQ38679628-F2BEACCC-0B7F-44E6-9B63-F77870EE4699Q38799963-C3031E70-2F9E-4C1B-89A3-0486FDC88D8BQ38824891-0176113B-2EA2-420F-9F48-2E6474A956C4Q38930367-FCD4EF06-F299-4D5E-8937-6C26737EFE5DQ38936292-FC02FF5F-C12A-41C9-898B-1FB265FB5A9AQ38956444-3F468DCB-9623-4078-87B2-E6498A0DA022Q39027385-CCEA7DD7-467E-4410-A128-AC99F718263DQ39128273-0E382381-3CF0-481C-A5DF-07DD15F59E68Q39183265-8203AEFA-22A9-4889-BB93-3ECE2EDD1AE9Q39237394-EBBE8224-E9C1-405B-9386-0B0B8934A77DQ39449763-13B78589-376F-480A-B90B-DFCD21EA5ABBQ40361438-FF407B2E-3CA9-41FC-9D30-1B7704A3479EQ40483555-FCC49379-1BBB-42CC-91AB-EB7A68FDEEBBQ40812047-E796F487-1C09-44FA-B28E-16332BCA5F4BQ41340094-918055FF-8501-4C30-B47B-58C5D3543DECQ41636361-0F8FF909-454B-4DE7-B01A-58D57BFE05D1Q41899534-C8A3F902-ADCE-48B3-BF2A-F26406340AA8Q42360043-134C7A27-1FB7-48E4-B205-AD7E983E369DQ42369300-2BDBDCE5-CB13-4140-9DF4-4C244042ED58
P2860
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Broad, Hybrid Capture-Based Ne ...... her Genomic Testing Approaches
@en
Broad, Hybrid Capture-Based Ne ...... er Genomic Testing Approaches.
@nl
type
label
Broad, Hybrid Capture-Based Ne ...... her Genomic Testing Approaches
@en
Broad, Hybrid Capture-Based Ne ...... er Genomic Testing Approaches.
@nl
prefLabel
Broad, Hybrid Capture-Based Ne ...... her Genomic Testing Approaches
@en
Broad, Hybrid Capture-Based Ne ...... er Genomic Testing Approaches.
@nl
P2093
P2860
P1476
Broad, Hybrid Capture-Based Ne ...... her Genomic Testing Approaches
@en
P2093
Alexander Drilon
Doron Lipson
Jeffrey S Ross
Joel R Greenbowe
Maria E Arcila
Mark G Kris
Naiyer A Rizvi
Phil Stephens
Sohail Balasubramanian
P2860
P304
P356
10.1158/1078-0432.CCR-14-2683
P407
P50
P577
2015-01-07T00:00:00Z